TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2655683

Group type: EXPERIMENTAL
Intervention: Homoeopathic preparation
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study: 198838

Group type: COMPARATOR
Intervention: Stable methadone intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gradual withdrawal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute withdrawal
Number of subjects: 0
Study: 30396098

Group type: EXPERIMENTAL
Intervention: BASICS+EC
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: BASICS
Number of subjects: 180

Group type: COMPARATOR
Intervention: Information
Number of subjects: 180
Study: 26780403

Group type: EXPERIMENTAL
Intervention: ResMed Mirage FX® (MFX)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control mask (Fisher & Paykel Zest®, HC407® or Philips EasyLife®)
Number of subjects: 195
Study: 25641242

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Normotensive infants not receiving vasopressor support)
Number of subjects: 20
Study: 25899533

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham RIPC (Control)
Number of subjects: 0
Study: 23306310

Group type: EXPERIMENTAL
Intervention: Factor V Leiden (FVL) mutation
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: G20210A prothrombin (FII) mutation
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Male sex and isolated DVT
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: FVL and FII mutations
Number of subjects: 753
Study: 21415581

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE) at peak infusion (40 μg/kg/min)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Cirrhosis group
Number of subjects: 71
Study: 18721181

Group type: EXPERIMENTAL
Intervention: Proactive airway clearance (AC) strategy, performed twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reactive airway clearance (AC) strategy, performed only in presence of chest infection
Number of subjects: 36
Study: 16669959

Group type: COMPARATOR
Intervention: Standard therapy (aminosalicylates and weekly tapered corticosteroids)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Heparin therapy (standard therapy plus enoxaparin 100 Anti‐Xa IU/kg/day subcutaneously)
Number of subjects: 34
Study: 12505947

Group type: EXPERIMENTAL
Intervention: Forced-air warming with one cotton blanket
Number of subjects: 300

Group type: COMPARATOR
Intervention: Reflective-blanket with one cotton blanket
Number of subjects: 300

Group type: COMPARATOR
Intervention: Two-cotton-blanket group
Number of subjects: 300
Study: 11728290

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (16 mg once daily, titrated to 32 mg as needed, with hydrochlorothiazide 12.5 mg as needed)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 9414372

Group type: EXPERIMENTAL
Intervention: Fluorescent lime-yellow test garment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fluorescent orange test garment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: White test garment
Number of subjects: 14
Study: 8126257

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 mcg/day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ibuprofen 2400 mg/day
Number of subjects: 9
Study: 3110681

Group type: EXPERIMENTAL
Intervention: L-carnitine added to dialysis fluid at a final concentration of 100 mumol/l
Number of subjects: 21
Study: 29618011

Group type: EXPERIMENTAL
Intervention: Diazoxide (DZX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study: 28589493

Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg once weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omarigliptin/omarigliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo/omarigliptin
Number of subjects: 0
Study: 24445038

Group type: EXPERIMENTAL
Intervention: Curcumin intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23558890

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg daily
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study: 20587129

Group type: EXPERIMENTAL
Intervention: Real rTMS treatment (n=14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham rTMS treatment (n=14)
Number of subjects: 28
Study: 18156403

Group type: EXPERIMENTAL
Intervention: Lycopene at a dose of 15 mg/d for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lycopene and Placebo
Number of subjects: 40
Study: 17094774

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol + ascorbic acid
Number of subjects: 352

Group type: COMPARATOR
Intervention: Sodium phosphate solution
Number of subjects: 352
Study: 12554889

Group type: EXPERIMENTAL
Intervention: Nitrite and nitrate levels in induced sputum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Peroxynitrite inhibitory activity in induced sputum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation between nitrite/nitrate levels and peroxynitrite inhibitory activity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation between peroxynitrite inhibitory activity and FEV(1) % predicted
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation between peroxynitrite inhibitory activity and FEV(1)/FVC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation between peroxynitrite inhibitory activity and carbon monoxide transfer factor (TLCO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation between peroxynitrite inhibitory activity and percentage of neutrophils
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation between peroxynitrite inhibitory activity and IL‐8 levels
Number of subjects: 30
Study: 10824502

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motor skills training (Control)
Number of subjects: 0
Study: 8648368

Group type: EXPERIMENTAL
Intervention: Doxorubicin, vincristine, cyclophosphamide, and fluorouracil (AVCF)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 249
Study: 7956768

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 44

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ultrasonography
Number of subjects: 44
Study: 3426370

Group type: EXPERIMENTAL
Intervention: Loperamide (Imodium) at an average dose of 20 to 25 drops/kg/24 h (0.16 to 0.20 mg/kg/24 h), given every 8 hours for at least 48 hours.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Loperamide (Imodium)
Number of subjects: 63
Study: 29998815

Group type: EXPERIMENTAL
Intervention: Pre-operative analgesics (paracetamol and ibuprofen)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 26983924

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intensive lifestyle and medical intervention (ILMI)
Number of subjects: 43
Study: 24048485

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 1279

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 1279
Study: 22542118

Group type: EXPERIMENTAL
Intervention: Treatment for mild gestational diabetes mellitus
Number of subjects: 932

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 932
Study: 20565484

Group type: EXPERIMENTAL
Intervention: Airsonett Airshower (AA) treatment with allergen-free air during night sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18388881

Group type: EXPERIMENTAL
Intervention: tesaglitazar
Number of subjects: 0
Study: 16185038

Group type: EXPERIMENTAL
Intervention: Computer-Assisted Orthopedic Surgery (CAOS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Image Intensifier Control
Number of subjects: 16
Study: 12641688

Group type: COMPARATOR
Intervention: Morphine (0.1 mg.kg(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg.kg(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tramadol (2 mg.kg(‐1))
Number of subjects: 60
Study: 10993491

Group type: EXPERIMENTAL
Intervention: Immunoadsorption plasmapheresis (IA)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Double filtration plasmapheresis (DF)
Number of subjects: 5
Study: 8869675

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA), size 3 or 4
Number of subjects: 11

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT) 8.0 mm
Number of subjects: 11
Study: 2005049

Group type: EXPERIMENTAL
Intervention: Parent-child interaction training (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal treatment (control group)
Number of subjects: 0
Study: 6193666

Group type: EXPERIMENTAL
Intervention: Admixture group: 20 ml dextran 1, 15% (Promiten) mixed with 500 ml dextran 70 (Macrodex) or dextran 40 (Rheomacrodex)
Number of subjects: 12060

Group type: COMPARATOR
Intervention: Preinjection group: 20 ml dextran 1, 15% administered before the infusion of dextran 70 or 40
Number of subjects: 12060
Study: 30854693

Group type: EXPERIMENTAL
Intervention: Medial approach with radiographic assistance
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Dorsolateral approach with radiographic assistance
Number of subjects: 98

Group type: COMPARATOR
Intervention: Medial approach without radiographic assistance
Number of subjects: 98

Group type: COMPARATOR
Intervention: Dorsolateral approach without radiographic assistance
Number of subjects: 98
Study: 30572932

Group type: EXPERIMENTAL
Intervention: Advocacy campaigns to reduce tobacco consumption through behavioral nudges via randomized controlled trials (RCTs)
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Carbon monoxide readings for short term smoking measurement
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: FEV1 and PEF values
Number of subjects: 985
Study: 27553442

Group type: EXPERIMENTAL
Intervention: PCFNB (bolus infusion of 3 ml with a lockout time of 30 min and no basal infusion)
Number of subjects: 56

Group type: COMPARATOR
Intervention: cFNB (basal infusion of 6 ml/h using a dummy bolus button)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PCFNB
Number of subjects: 56

Group type: COMPARATOR
Intervention: cFNB
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PCFNB and cFNB
Number of subjects: 56
Study: 24132707

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron film-coated tablets (test product)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zofran (reference product)
Number of subjects: 0
Study: 22263710

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT) initiated prior to release from incarceration
Number of subjects: 0
Study: 19021604

Group type: EXPERIMENTAL
Intervention: Single preoperative dose of ciprofloxacin (2 tablets of 500 mg each, 2 hours before biopsy)
Number of subjects: 288

Group type: COMPARATOR
Intervention: 3-day course of ciprofloxacin
Number of subjects: 288
Study: 17618422

Group type: EXPERIMENTAL
Intervention: New remission criteria
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: New remission criteria with item threshold 'at best very mild symptoms'
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: Psychotic symptoms component
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: CGI severity score mild or better
Number of subjects: 1708

Group type: COMPARATOR
Intervention: At least 50% BPRS reduction
Number of subjects: 1708

Group type: COMPARATOR
Intervention: CGI improvement score of at least 'much better'
Number of subjects: 1708
Study: 14996607

Group type: EXPERIMENTAL
Intervention: Xanthine oxidase inhibition in smokers
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 24

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 24
Study: 12537268

Group type: EXPERIMENTAL
Intervention: Written standardized information and non-standardized verbal information (intervention group)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Non-standardized verbal information (control group)
Number of subjects: 123
Study: 9814476

Group type: EXPERIMENTAL
Intervention: ERalpha and ERbeta mRNA expression in prolactinomas (n = 14)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: ERbeta mRNA expression in tumors expressing PRL and GH (n = 6)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: ERbeta mRNA expression in null cell tumors (n = 24)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: ERbeta mRNA expression in gonadotrope tumors (n = 21)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: ERbeta mRNA expression in tumors containing only GH (n = 6)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Expression of ERalpha mRNA splice variants in normal pituitaries (n = 6)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Expression of ERalpha variants in ER-positive prolactinomas
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Expression of ERalpha exon 7 deletion variant in gonadotropin tumors
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Novel ERbeta mRNA splice variant in ERbeta-positive tumors
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Immunoblotting analysis of ERalpha and ERbeta proteins
Number of subjects: 77
Study: 7858770

Group type: EXPERIMENTAL
Intervention: Tc-99m-sestamibi SPECT
Number of subjects: 38

Group type: COMPARATOR
Intervention: Tl-201 SPECT
Number of subjects: 38

Group type: COMPARATOR
Intervention: Tc-99m-sestamibi and Tl-201
Number of subjects: 38
Study: 2802123

Group type: EXPERIMENTAL
Intervention: Propofol 2.15 mg/kg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Thiopentone 4.53 mg/kg
Number of subjects: 21
Study: 345570

Group type: EXPERIMENTAL
Intervention: Oral iron therapy for anaemic adult villagers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral iron and/or TCE for children aged 5-14 years
Number of subjects: 0
Study: 31300842

Group type: EXPERIMENTAL
Intervention: Needle aspiration
Number of subjects: 182

Group type: COMPARATOR
Intervention: Incision and drainage
Number of subjects: 182
Study: 27729167

Group type: EXPERIMENTAL
Intervention: Genistein treatment
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 218
Study: 26222559

Group type: EXPERIMENTAL
Intervention: ISIS 304801 (100 mg)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ISIS 304801 (200 mg)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ISIS 304801 (300 mg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (monotherapy)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ISIS 304801 (200 mg, add-on to fibrates)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ISIS 304801 (300 mg, add-on to fibrates)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (add-on to fibrates)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ISIS 304801 (all doses)
Number of subjects: 85
Study: 23821878

Group type: EXPERIMENTAL
Intervention: Simultaneous technique (two injections at the same time)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sequential technique (one injection after the other)
Number of subjects: 72
Study: 21875546

Group type: EXPERIMENTAL
Intervention: BUD/FM pMDI 160/4.5 μg × 2 inhalations (320/9 μg) twice daily
Number of subjects: 250

Group type: COMPARATOR
Intervention: BUD pMDI 160 μg × 2 inhalations (320 μg) twice daily
Number of subjects: 250
Study: 18001802

Group type: EXPERIMENTAL
Intervention: Toremifene 80 mg per day
Number of subjects: 1392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1392
Study: 16826107

Group type: COMPARATOR
Intervention: Cemented fixation
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Uncemented (HA coated) with screws
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Uncemented (HA coated) without screws
Number of subjects: 85
Study: 12566865

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) with verteporfin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11097536

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.005, 0.01, 0.02, or 0.05 mg x kg(‐1))
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Edrophonium (0.1, 0.2, 0.4, or 1 mg x kg(‐1))
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 128
Study: 9347278

Group type: EXPERIMENTAL
Intervention: Abdominal hot can configuration (common anode with proximal coil)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Abdominal hot can configuration
Number of subjects: 30
Study: 8443481

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg once daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 21
Study: 3718908

Group type: EXPERIMENTAL
Intervention: Topical haloperidol
Number of subjects: 20
Study: 29792287

Group type: EXPERIMENTAL
Intervention: GLPG1690 (600 mg oral once daily for 12 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: GLPG1690
Number of subjects: 23
Study: 26878554

Group type: EXPERIMENTAL
Intervention: Active rTMS (1000 pulses; 1 Hz; 90% of the tibialis anterior motor threshold)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 20
Study: 24519563

Group type: EXPERIMENTAL
Intervention: Aminophylline (75 mg intravenous, administered 90 seconds after (99m)Tc‐tetrofosmin injection)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 22939709

Group type: EXPERIMENTAL
Intervention: Free bednet distribution
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Subsidised bednet through agricultural loan programmes
Number of subjects: 516
Study: 20923473

Group type: EXPERIMENTAL
Intervention: 400 IU cholecalciferol for 4 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1200 IU cholecalciferol for 4 months
Number of subjects: 0
Study: 18927301

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry test using five monoclonal antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 0
Study: 16805930

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 70

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 70
Study: 14669885

Group type: EXPERIMENTAL
Intervention: Practice (infants who practiced the target actions before the retention interval)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No practice (infants who did not practice the target actions before the retention interval)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Practice (infants who practiced)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No practice (infants who did not practice)
Number of subjects: 0
Study: 10815320

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (FEC-G) in addition to amikacin-ceftriaxone and other antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antibiotic therapy without granulocyte colony-stimulating factor
Number of subjects: 0
Study: 8997670

Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (standard therapy)
Number of subjects: 10
Study: 1472833

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg per day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg per day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Simvastatin 40 mg per day + Gemfibrozil 450 mg per day
Number of subjects: 19
Study: 6424087

Group type: EXPERIMENTAL
Intervention: Intravenous nitrogen intake (290 to 579 mg/kg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrogen intake (280 mg/kg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommended intravenous amino acid intakes (2.3 to 2.7 g/kg/d)
Number of subjects: 0
Study: 30514351

Group type: EXPERIMENTAL
Intervention: Electronic Symptom Assessment‐Cancer (ESRA‐C) intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (electronic assessment alone)
Number of subjects: 0
Study: 26850265

Group type: EXPERIMENTAL
Intervention: 12-month aerobic-resistance exercise intervention (3 times/week)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Home-based physical activity group
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Subjects on Tamoxifen or no endocrine therapy
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Subjects on aromatase inhibitors (AIs)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Subjects with serum Vitamin D levels 20-29 ng/mL
Number of subjects: 154
Study: 25155251

Group type: EXPERIMENTAL
Intervention: Progression Free Survival Rate at 9 weeks (PFSR-9)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Progression Free Survival Rate at 18 weeks (PFSR-18)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Validation study results for PFSR-9
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Validation study results for PFSR-18
Number of subjects: 605

Group type: COMPARATOR
Intervention: Best overall response in validation study
Number of subjects: 605
Study: 22863540

Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 46
Study: 20441721

Group type: EXPERIMENTAL
Intervention: In virtuo plus in vivo exposure
Number of subjects: 31

Group type: COMPARATOR
Intervention: In vivo exposure alone
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Motivation
Number of subjects: 31